Registered number
09591401
Year end:
31 May 2024
SARWAR ONCOLOGY LIMITED
UNAUDITED FILLETED ACCOUNTS
FOR THE YEAR
ENDED 31 MAY 2024
SARWAR ONCOLOGY LIMITED
Registered number: 09591401
Balance Sheet
as at 31 May 2024
Notes 2024 2023
£ £
FIXED ASSETS
Tangible assets 3 273 364
CURRENT ASSETS
Debtors 4 31,872 30,774
Cash at bank and in hand 277,581 246,031
309,453 276,805
CREDITORS: amounts falling due within one year 5 (15,234) (27,153)
NET CURRENT ASSETS 294,219 249,652
TOTAL ASSETS LESS CURRENT LIABILITIES 294,492 250,016
Provisions for liabilities (51) (69)
NET ASSETS £ 294,441 £ 249,947
CAPITAL AND RESERVES
Called up share capital 1 1
Profit and loss account 294,440 249,946
SHAREHOLDER'S FUNDS £ 294,441 £ 249,947
The director is satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The member has not required the company to obtain an audit in accordance with section 476 of the Act.
The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account is not delivered to Companies House.
Dr M N Sarwar
Director
Approved by the board on 16 March 2025
SARWAR ONCOLOGY LIMITED
Notes to the Accounts
for the year ended 31 May 2024
1 ACCOUNTING POLICIES
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover
Turnover is measured at the fair value of the consideration receivable, net of discounts and value added taxes. Turnover from the sale of any goods is recognised when goods are delivered and legal title has passed.
Tangible fixed assets
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
Office equipment 25% p.a. on a reducing balance basis
Deferred taxation
Full provision is made for deferred taxation resulting from timing differences between the recognition of gains and losses in the accounts and their recognition for tax purposes. Deferred taxation is calculated on a non-discounted basis at the tax rates which are expected to apply in the periods when the timing differences are expected to reverse.
2 EMPLOYEES 2024 2023
Number Number
Average number of persons employed by the company
(excluding directors with no specific service contract) - -
SARWAR ONCOLOGY LIMITED
Notes to the Accounts
for the year ended 31 May 2024
3 TANGIBLE FIXED ASSETS
Office Equipment
£
Cost
At 1 June 2023 1,532
At 31 May 2024 1,532
Depreciation
At 1 June 2023 1,168
Charge for the year 91
At 31 May 2024 1,259
Net book value
At 31 May 2024 £ 273
At 31 May 2023 £ 364
4 DEBTORS 2024 2023
£ £
Trade debtors 8,185 3,652
Director's loan account 17,194 18,645
Other debtors 6,493 8,477
£ 31,872 £ 30,774
Amounts due after more than one year included above £ 5,588 £ 6,074
5 CREDITORS: amounts falling due within one year 2024 2023
£ £
Trade creditors 2,408 67
Corporation tax 10,966 24,326
Other creditors 1,860 2,760
£ 15,234 £ 27,153
SARWAR ONCOLOGY LIMITED
Notes to the Accounts
for the year ended 31 May 2024
6 LOANS TO DIRECTORS
Description and conditions B/fwd Paid Repaid C/fwd
£ £ £ £
Dr M N Sarwar
Temporary loan with interest at the official rate applied to beneficial loans 18,645 - (1,451) 17,194
£ 18,645 £ - £ (1,451) £ 17,194
7 CONTROLLING PARTY
At the date of approval of these accounts Dr M N Sarwar controls the company by virtue of his holding 100% of the issued share capital.
8 OTHER INFORMATION
Sarwar Oncology Limited is a private company limited by shares and incorporated in England. Its registered office is:
Titsey Estate Office
Pilgrims Lane
Oxted
Surrey
RH8 0SE
The accounts are for the individual company and are presented in Sterling which is the functional currency of the company.
SARWAR ONCOLOGY LIMITED 09591401 false 2023-06-01 2024-05-31 2024-05-31 VT Final Accounts April 2024 Dr M N Sarwar No description of principal activity 09591401 2022-06-01 2023-05-31 09591401 core:WithinOneYear 2023-05-31 09591401 core:ShareCapital 2023-05-31 09591401 core:RetainedEarningsAccumulatedLosses 2023-05-31 09591401 core:AfterOneYear 2023-05-31 09591401 2023-06-01 2024-05-31 09591401 bus:PrivateLimitedCompanyLtd 2023-06-01 2024-05-31 09591401 bus:AuditExemptWithAccountantsReport 2023-06-01 2024-05-31 09591401 bus:Director40 2023-06-01 2024-05-31 09591401 core:PlantMachinery 2023-06-01 2024-05-31 09591401 bus:Director1 2023-06-01 2024-05-31 09591401 bus:Director1 1 2023-06-01 2024-05-31 09591401 countries:England 2023-06-01 2024-05-31 09591401 bus:FRS102 2023-06-01 2024-05-31 09591401 bus:FilletedAccounts 2023-06-01 2024-05-31 09591401 2024-05-31 09591401 core:WithinOneYear 2024-05-31 09591401 core:ShareCapital 2024-05-31 09591401 core:RetainedEarningsAccumulatedLosses 2024-05-31 09591401 core:PlantMachinery 2024-05-31 09591401 core:AfterOneYear 2024-05-31 09591401 bus:Director1 1 2024-05-31 09591401 2023-05-31 09591401 core:PlantMachinery 2023-05-31 09591401 bus:Director1 1 2023-05-31 iso4217:GBP xbrli:pure